{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT05701709","nct_id":"NCT05701709","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05701709. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":null,"label":"SHR-A2102","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-08-31","type":"ESTIMATED"},"conditions":["Advanced Solid Tumors"],"enrollment":{"count":395,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"SHR-A2102","type":"DRUG"}],"last_update":"2025-07-22","lead_sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","official_title":"An Open-Label, Single-Arm, Multi-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of SHR-A2102 in Patients With Advanced Solid Tumors","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-08-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of participants with adverse events","timeFrame":"24 months"},{"measure":"Maximum tolerated dose (MTD)","timeFrame":"12 weeks"},{"measure":"Recommended Phase 2 dose (RP2D)","timeFrame":"24 months"},{"measure":"Dose Limiting Toxicity (DLT)","timeFrame":"3 weeks"}],"references":[{"citation":"Zhong R, Hong H, Yan M, Wang Q, Zhang Y, Lan Q, Luo Y, Zhang L, Xu H, Guo S, Guo W, Ma J, Zhang L, Wu L, Liu Z, He W, Sun Y, Chen K, Huang J, Han G, Nian W, Zhang M, Ren S, Qiao R, Li X, Yu M, Hu J, Huang Y, Song L, Shi W, Zhong H. SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. Lancet Oncol. 2026 Sep;27(9):1146-1157. doi: 10.1016/S1470-2045(26)00238-X.","pmid":"42636836","type":"DERIVED"}],"start_date":{"date":"2023-04-06","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT05701709"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05701709"}